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Acute-on-Chronic Liver Failure (ACLF) in cirrhosis has recently been 
characterized by the CANONIC study as a highly prevalent syndrome 
consisting in acute decompensation (AD), organ/system failure(s) and high 
28-day mortality (32%).1 Until the publication of the CANONIC study, 
conventional scoring systems developed to define the prognosis of patients 
with cirrhosis such as the Child Pugh and Model for End-Stage Liver Disease 
(MELD) scores or their variations were the only tools available to 
prognosticate in this patient cohort. They were limited in their prognostic 
accuracy in ACLF due to a failure to incorporate two central prognostic 
determinants; (a) extra-hepatic organ failures and (b) measures of systemic 
inflammation, which fundamentally underlie the pathophysiological basis of 
the syndrome.  
 
The CANONIC study1 was a large scale multi-centre prospective clinical study 
evaluating over 1300 patients hospitalized with a complication of cirrhosis was 
conducted to describe the clinical phenotypes of patients with acute on 
chronic liver failure (ACLF). A further specific aim of the study was to assess 
the currently available prognostic scoring systems and develop a new score if 
required. Indeed, the aims of the study we met and led to the description of 
the ACLF phenotype and the development and validation of novel scoring 
systems for the prognosis of patients with ACLF and acute decompensation 
(AD).2,3 The resultant CLIF Consortium ACLF score (CLIF-C ACLFs) has 
since been independently validated with proven superior prognostic accuracy 
for ACLF compared to conventional measures such as MELD, and Child-
Pugh scores. The temporal clinical course of these patients was identified as 
an important prognostic indicator and dynamic assessment of the patient’s 
clinical course using these scoring systems has also been validated as an 
important prognostic tool.4  
 
This chapter will consider the phenotype of ACLF and acute decompensation 
(AD) and how the nature of this influences outcome. Secondly, a description 
of the scoring systems developed from the CANONIC study data, how they 
compare with other scoring systems and a proposed algorithm of how they 
may be applied in clinical practice, in particular liver transplantation. Finally, 
we will discuss the PIRO concept, which may be a useful model to consider 
the development of new approaches to therapy of ACLF.  
 
The main results of the CANONIC study 
The data from the CANONIC study showed that the presence of ACLF as 
diagnosed using an organ failure scoring system, distinguished patients with a 
28-day mortality of greater than 15% (referred to as ACLF group) and 
described several grades of ACLF. A modified sequential organ failure 
assessment (SOFA) score, evaluating liver, kidney, brain, coagulation, 
circulation and respiratory function was used (Tables 1, 2). ACLF grades (1-3) 
were found to be highly predictive of mortality with strikingly different 
outcomes (Figure 1). In addition to ACLF score at presentation, the temporal 
course of ACLF (particularly over the first 7 days) was found to be strongly 
predictive of outcome. Heterogeneity was observed in the ACLF clinical 
course in which improvement was observed in 50% of patients, a steady or 
undulating course in 30% with deterioration in 20% of cases. The frequency of 
the clinical course was dependent upon the initial ACLF grade. Patients who 
resolved to no ACLF were found to have outcomes similar to those with acute 
decompensation. Conversely, patients with ACLF-3 had a very high mortality. 
Once ACLF was established, the prognosis relied on factors independent of 
the precipitating events such as the presence of systemic inflammation at the 
outset.1-4 
 
Scoring Systems to Assess ACLF 
A window of opportunity exists in ACLF to reverse organ failure and improve 
outcome but accurate prognostic tools are required to inform the clinical 
decision-making process. This allows for better stratification of patients to 
determine suitability for intensive care, fast-track listing for liver 
transplantation, or determination of futility of further supportive care. Modified 
scoring systems validated in large prospective clinical studies such as the 
CANONIC study have facilitated more accurate prognostication in patients 
with ACLF. The recently described CLIF scoring systems CLIF-C OF score, 
the CLIF-C ACLF score and the CLIF-C AD score discriminate between ACLF 
and acute decompensation and prognosticate allowing a step-wise algorithm 
for a rational management of patients with decompensated cirrhosis.  
 
CLIF-OF score and CLIF-ACLF score 
The CLIF-OF score (Table 1,2) may be used on admission to determine the 
presence or absence of ACLF. The scores are freely available on the CLIF 
Consortium website and also as an app that is downloadable on any mobile 
platform (ACLF Calculator, Cyberliver, UK). Response to treatment of ACLF 
patients may be monitored by daily calculation of the CLIF-C ACLF score, 
incorporating the CLIF-OF score, age and white cell count. Ultimately, 
resolution of ACLF is the most important determinant of short and medium 
term mortality and the CLIF-C scores provide an objective measure of this.  
 
Patients with high CLIF-C ACLF scores may be considered for liver 
transplantation. If ineligible for transplantation without a demonstrable 
treatment response in ACLF score by days 3-7, consideration should be made 
as to the appropriate ceilings of management.2,4  
 
CLIF-C Acute Decompensation score (CLIF-AD)  
The CLIF-AD score may be used to stratify patients with acute 
decompensation but not ACLF into high, medium and low risk categories of 
mortality. The CLIF-C AD score includes age, white cell count, serum sodium, 
serum creatinine and INR. Variables in each score were combined to 
generate a score system ranging from 0 to 100. High-risk acute 
decompensation has been shown to have similar outcomes to ACLF-1 and 
patients with this diagnosis should be managed in a level 2/3 care 
environment. Patients in medium risk (score 46-59) have a 3-month mortality 
of 31% and warrant further management within level 1 care. Conversely, low 
risk patients (score <45) have a 3-month mortality of 1.8% and thus may be 
considered for early discharge. A proposed algorithm for the assessment of 
patients with ACLF and acute decompensation is highlighted in Figure 2.3 
 
Other Scoring Systems 
The CLIF-OFs and CLIF-SOFA scores have been shown to have superior 
prognostic accuracy compared to conventional measures such as MELD, 
MELD-Na and Child-Pugh score (Figure 3).5 Other scoring system that is 
relevant in the patients with infection was suggested by NACSELD and is a 
variant of the organ failure scoring system. Many aetiology specific scoring 
systems exist such as the Maddrey score, Lille score, Glasgow score that are 
specific for patients with acute alcoholic hepatitis. How the CLIF scores 
compare with these scores will have to be assessed in prospective studies in 
the future. Whilst capturing parameters relevant to hepatic failure, none of 
these commonly used scoring systems capture number of organ failures or 
incorporate markers of inflammation, key prognostic determinants in ACLF. In 
context of acute decompensation, the predictive value of the CLIF-C AD score 
improves prediction of 3 month and 12 month mortality by 10-20% compared 
to MELD, MELD-Na, and Child-Pugh scores.  
 
Patient Selection for Liver Transplant in ACLF 
At present, there is no priority given to patients being allocated organs for liver 
transplantation. 5-year survival outcomes following liver transplant for ACLF 
are good, ranging between 74 and 90 %. Eligibility may be precluded by 
number of organ failures, sepsis, co-morbidity, age or active alcoholism. The 
pre-transplant condition of patients with ACLF may play a key role in 
determining outcome and therefore careful patient selection is crucial. 
 
Given the labile and rapidly progressive nature of the disease, a narrow 
window of opportunity exists when patients are sufficiently stable to consider 
this option. Current level of understanding does not allow clarity about which 
patients need urgent transplantation, regular transplantation, no 
transplantation or they are too sick to transplant (Figure 4).  Medical response 
to supportive therapy has been conventionally measured by scoring systems 
such as MELD. The limitations inherent in these are highlighted by Duana et 
al who observed that MELD score did not predict outcomes of patients with 
hepatitis B ACLF following orthotopic liver transplantation.6 The data from the 
CANONIC study also very clearly demonstrates that the MELD score, which is 
what is currently used for organ allocation, under estimates the risk of death 
of ACLF patients by 20-30% seriously disadvantaging ACLF patients.2 
Dynamic assessment of CLIF-C ACLF scores may facilitate this decision-
making process although further validation studies are required to determine a 
more precise algorithm for optimal timing of transplantation. Furthermore, 
transplantation is usually only considered in patients assessed and listed for 
transplantation before an episode of ACLF.2  
 
Data regarding liver transplantation outcomes for ACLF patients are limited 
and interpretation is complicated by variable definitions of ACLF, small patient 
cohorts, retrospective analysis and lack of availability of long term follow up 
data. 4.9% and 15% of patients from the CANONIC patient cohort with ACLF 
underwent transplantation within 28 and 90 days of admission respectively. 
Survival of patients with ACLF-2 or -3 without transplantation was less than 
20% but 80% with transplantation, comparable to patients transplanted 
without ACLF.   
 
Only one study (n=238) used intention-to-treat analysis and showed a 5-year 
post-transplant survival of greater than 80% for patients eligible for 
transplantation (<25% of patient cohort).7 The median transplant-free survival 
time was 48-days with deaths most commonly secondary to multi-organ 
failure.  Successful transplant outcomes in carefully selected patients with 
corticosteroid-resistant acute alcoholic hepatitis further reinforce the 
importance of good patient selection using accurate prognostic criteria. 
Patients with ACLF appear to tolerate marginal grafts particularly well. 
Survival and post-transplant length of stay is known to be worse for patients 
hospitalized at the time of surgery than in those at home and markedly worse 
still for those in level 3 care. Increasing recipient age (>60 years) is 
consistently associated with increased mortality. 
 
Inclusion of high-risk ACLF sub-groups as an indication for high urgency 
allocation is not currently practiced in most countries but should be the subject 
of further studies particularly given the good outcomes described. The US 
experience of this strategy is highly favourable with an improvement in waiting 
list mortality of 30% with no significant increase in post-transplant mortality. 
Expedited transplantation assessment should be also be considered for 
survivors of ACLF after discharge from the intensive care unit due to a 
substantial increase in medium-term mortality.  
 
Future specific therapies for ACLF 
At present, there is no specific therapy for ACLF. This is not surprising as it is 
only very recently that this syndrome has been defined. It is clear that the 
syndrome is complex and therefore, treatment strategies for ACLF are likely 
to be complex. In order to develop new therapies, two concepts may be 
useful. The first is the concept of an ACLF spiral, a hypothesis that defines the 
process of progression of liver injury started by systemic inflammation and 
perpetuated by effect of cell death, multiple organ failure and immune 
dysfunction. The second is the PIRO concept.8 This hypothesis suggests that 
a patient with ACLF is categorized into 4 domains; P: Predisposition, I: Injury 
(precipitating event), R: Response and O: type and number of organ failures. 
Using this concept, one can envisage therapeutic strategies targeted to 
modulated each of these variables to try and address the ACLF spiral. 
 
The use of Tenofovir attempts to target the predisposing factor as well as the 
precipitating event in patients developing ACLF due to HBV reactivation and 
has been shown to be effective in a small study (targeting P).9 Granulocyte 
colony stimulating factor has been shown to reduce mortality in a subgroup of 
patients but the mechanisms how this is achieved is uncertain (possibly 
targeting R).10 Therapies aimed at targeting products of cell death and 
inflammation such as pan-caspase inhibitors have been studied in a small 
group of patients (final data not yet available) (targeting R).11 More recently, 
on going treatment with beta-blockers were shown to reduce the mortality of 
patients developing ACLF, possibly by modulating inflammatory reponse 
(targeting R).12 In patients with spontaneous bacterial peritonitis, 
administration of albumin in addition to antibiotics reduces mortality by 
improving inflammatory response and also improving circulatory function 
(targeting I).13 Targeting end organ dysfunction such as the kidneys using 
terlipressin and albumin has been shown to be effective (targeting O).14 In a 
trial of albumin dialysis in patients with hepatic encephalopathy, the 
improvement in its severity was shown to improve patient survival irrespective 
of the kind of treatment used (targeting O).15 Extracorporeal liver support is a 
good example of a type of intervention that targets either the removal of 
mediators of cell death or attempts to reduce inflammation or provide liver 
support in the case of bioartificial devices (aims to target multiple factors; I, R 
and O). None of the available devices have been shown to be useful in 
reducing mortality of ACLF patients.16 
 
Conclusions 
ACLF is being increasingly recognized as an important cause of mortality of 
cirrhotic patients and the recent studies providing information about its 
diagnostic and prognostic criteria allows this syndrome to be better defined 
pathophysiologically. Once, the syndrome is better understood, novel, 
targeted therapies can be further developed. 
  
Figure Legends 
 
Figure 1. Mortality of patients with acute decompensation of cirrhosis and 
acute on chronic liver failure (Modified from Moreau et al. Gastroenterology 
2013) 
 
Figure 2. Proposed algorithm for diagnosis and risk stratification of ACLF and 
acute decompensation (Data from Jalan et al. J Hepatol 2014; J Hepatol 
2015) 
 
Figure 3. This figure shows the percentage improvement in the prediction 
error of the MELD, MELD Na and the Pugh Score in comparison with the 
CLIF-C ACLF score. (Data from Jalan et al. J Hepatology 2014) 
 
Figure 4. A cartoon depicting potential outcomes of patients with ACLF and 
the possible timings of liver transplantation. 
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Table 1  Diagnostic criteria of ACLF (Data reproduced from Jalan et al. J 
Hepatology 2014) 
 
Diagnosis Criteria 
 
No ACLF  Patients with no organ failure 
 Patients with single hepatic, coagulation, circulation 
or respiratory failure, serum creatinine <1.5 mg/dl 
and no HE 
 Patient with cerebral failure and serum creatinine 
<1.5 mg/dl 
 
ACLF-1  Patients with renal failure 
 Patients with other single organ failure with serum 
creatinine ≥1.5 and<2 mg/dl and/or HE grade 1-2.   
 
ACLF-2  Patients with 2 organ failures 
 
ACLF-3  Patients with 3 or more organ failures 
 
 
 
 
 
  
Table 2 The CLIF Organ Failure scoring system (Jalan et al., J Hepatol. 2015 
62:831-40.) 
 
Organ 
System 
Score = 1 Score = 2 Score = 3 
Liver (mg/dl) Bilirubin < 6 6 ≤ Bilirubin ≤ 12 Bilirubin >12 
Kidney 
(mg/dl) 
Creatinine  <2 Creatinine ≥2 <3.5 Creatinine ≥3.5 or 
renal replacement 
Brain  
(West-
Haven) 
Grade 0 Grade 1-2 Grade 3-4 
Coagulation INR < 2.0 2.0 ≤ INR < 2.5 INR ≥ 2.5 
Circulation MAP ≥70 
mm/Hg 
MAP <70 mm/Hg Vasopressors 
Respiratory: 
PaO2/FiO2 
 or 
SpO2/FiO2  
>300 
>357  
≤300 - > 200 
>214- ≤357  
≤200 
≤214  
The colored areas represent organ failure. 
INR: International Normalised Ratio; MAP: Mean arterial pressure; PaO2: 
Partial pressure of oxygen; SpO2: Oxygen saturation; FiO2: Fractional 
inspired oxygen  
 
 
 
 
